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he dawning of a new decade is an appropriate
time to reflect on the tremendous progress that has been
made in human genomic research. In 2010, with whole-
genome sequencing becoming increasingly affordable,
the promise of large-scale human genomic research stud-
ies involving hundreds, thousands, and even hundreds of
thousands of individuals is rapidly becoming a reality.
The next generation of human genomic research will
occur on a scale that would have been nearly unfath-
omable at the start of the last decade, when the publica-
tion of the Human Genome Project’s first draft results
was still pending.
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The cost of a diploid human genome sequence has dropped from about $70M to $2000 since 2007—even as the standards
for redundancy have increased from 7x to 40x in order to improve call rates. Coupled with the low return on investment
for common single-nucleotide polylmorphisms, this has caused a significant rise in interest in correlating genome sequences
with comprehensive environmental and trait data (GET). The cost of electronic health records, imaging, and microbial,
immunological, and behavioral data are also dropping quickly. Sharing such integrated GET datasets and their interpre-
tations with a diversity of researchers and research subjects highlights the need for informed-consent models capable of
addressing novel privacy and other issues, as well as for flexible data-sharing resources that make materials and data avail-
able with minimum restrictions on use. This article examines the Personal Genome Project’s effort to develop a GET data-
base as a public genomics resource broadly accessible to both researchers and research participants, while pursuing the
highest standards in research ethics. 
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results on June 26, 2000, it published a compound human
genome sequence containing genetic information from sev-
eral volunteers. Seventy percent of the final sequence was
obtained from one anonymous individual, while the remain-
ing 30% came from a number of different individuals. From
the first amalgamated human genome sequence—which
was refined in 2003 and continues to be updated and refined
to this day—private and public research efforts have gone
on to sequence numerous individual human genomes with
increasing speed and detail and decreasing time and cost.
The acceleration of whole-genome sequencing in the
research context necessitates new perspectives and models
that enable scientists and society to learn as much as pos-
sible from this rapidly expanding dataset while still respect-
ing important ethical, legal, and social norms.
The Personal Genome Project (PGP),
1 an ambitious
research study directed by faculty members in the
Department of Genetics at Harvard Medical School, aims
to recruit as many as 100 000 informed participants to con-
tribute genomic sequence data, tissues, and extensive envi-
ronmental, trait, and other information to a publicly acces-
sible and identifiable research database.
In this review we describe the Personal Genome Project
itself, focusing on its unique structural features and the
rationale behind the project’s design. We also elucidate the
changing scientific and social landscape that makes the
PGP’s model of open consent and public data access
increasingly important to the furtherance of human
genomic research.
The PGP’s mission
In contrast to research studies that focus on small sub-
sets of traits within narrowly defined human populations
exhibiting single diseases, the PGP was conceived with
an expansive mission. From the outset, the mission of the
project (Table I) has been to develop a broad-based, lon-
gitudinal, and participatory research study that will facil-
itate a comprehensive understanding of the project’s
participants at the genomic level and beyond. 
The PGP is constructed with the recognition that our
desire to truly understand the genesis of most complex
human traits—from dread diseases to the talents and
quirks that make us each uniquely human—could only
be satisfied by examining genomic information in con-
text and by surrounding it with the richest possible data
from the widest possible array of supplemental sources.
By supplementing genomic sequence data with the col-
lection and analysis of tissues and extensive environ-
mental and trait data, and by making these data publicly
accessible to researchers worldwide, the PGP aims to
improve understanding of the ways in which genomes
plus environments ultimately equal traits (Figure 1).
The PGP is more than just a research repository. In addi-
tion to its publicly accessible research database, the PGP,
which is supported by the nonprofit PersonalGenomes.org,
also works to disseminate genomic technology and knowl-
edge at a global level, thereby producing tangible and
widely available improvements in the understanding and
management of human health and disease. The PGP also
Basic research
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The Personal Genome Project’s Mission Statement
The mission of the Personal Genome Project is to encourage the development of personal genomics technology and practices that: 
￿ are effective, informative, and responsible 
￿ yield identifiable and improvable benefits at manageable levels of risk 
￿ are broadly available for the good of the general public 
To achieve this mission we will build a framework for prototyping and evaluating personal genomics technology and practices at increasing 
scales. In support of this goal, we will: 
￿ develop a broad vision for how personal genomes may be used to improve the understanding and management of human health and 
disease 
￿ provide educational and informational resources for improving general understanding of personal genomics and its potential 
￿ recruit individuals interested in obtaining and openly sharing their genome sequences, related health and physical information, and 
reporting their experiences as a participant of the project on an ongoing basis 
￿ develop technologies to improve the accessibility of personal genome sequencing 
￿ foster dialog with research communities, industries, and public and governmental bodies with interests in personal genomics, and related 
ethical, legal, and social issues (ELSI)
￿ develop tools for interpreting genomic information and correlating it with personal medical and biological information
Table I. PGP’s Mission Statement, available at: htttp://www.personalgenomes.org/mission.html.
1
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ethical, legal, and social issues (ELSI) associated with
large-scale whole-genome sequencing, particularly in the
areas of privacy, informed consent, and data accessibility.
The PGP is, and is intended to be, a research project that
is constantly in progress, exploring the boundaries of
human genomic research in a way that produces maxi-
mal advances in scientific understanding and public
understanding and well-being, while striving to reach
beyond what is minimally required to satisfy its ethical,
legal, and social obligations to its participants. In the sec-
tions that follow we report on unique aspects of the PGP
relating to technology development, integrative
genomics, and human subject research protocols, as well
as describe the development and current state of the
PGP.
Key developments in 
human genome sequencing
The PGP derives its impetus and importance from his-
toric breakthroughs in understanding and analysis of
DNA. DNA comprises only a very small fraction of a
cell (~3% dry weight E. coli), and its role as the mole-
cule primarily responsible for transmission of genetic
traits was not recognized until a series of discoveries
beginning in the 1940s. The emergence in 1953 of a clear
concept of DNA as a double-helical structure compris-
ing a pair of complementary strings of four elementary
bases (the nucleotides A, C, G, and T) crystallized inter-
est in determining the DNA sequences of genes and the
sequence differences responsible for disease, and set the
stage for over four decades of development of ever more
efficient and comprehensive sequencing methods. Table
II describes this history by a set of milestones that take
one from the early beginnings of DNA sequencing up
through delivery of draft human genome sequences in
2001 to 2003. In the 38 years between 1965, when Robert
Holley and colleagues at Cornell and the US
Department of Agriculture sequenced a 77 nt RNA
gene after 4 years of effort, and 2003, when the public
Human Genome Project (HGP) declared that it had met
its goals regarding delivery of a ~3Gbp human genome
sequence, the size of DNA sequence that could be
accommodated by sequencing technology improved ~30
million-fold. 
Post-HGP sequencing—towards 
whole diploid genomes
Notably, the HGP had delivered only a single human
genome sequence that was a composite built from a small
number of deidentified individuals, while the competing
nonpublic human genome project merged in data from an
identified individual (Craig Venter); both were haploid
estimates. As recognized from the beginning of the HGP,
many additional resources would be needed to under-
stand the functions of the genes laid out in these “refer-
ence” human genomes, and to identify the sequence dif-
ferences between individuals that contribute to individual
traits, health, and disease. Indeed, as the HGP ended, pro-
jects were already under way to identify large numbers of
genetic differences from the HGP-derived reference
genome in different human populations that could sub-
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Figure 1. Genome + Environment = Traits (GET) equation. Envirome: the totality of environmental influences; VDJ-ome: the DNA sequences of the entire
repertoire of an individual’s immunoglobulin and T-cell receptors, which reflect a lifetime of antigenic exposures; Microbiome: the billions of
commensal, symbiotic, and pathogenic micro-organisms that share our body space; Epigenome: the totality of programmed biochemical and
structural modifications to genomic DNA that regulate organism or phenotype development. (see overview in Table III).
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large numbers of individuals, a strategy that has since
given rise to more than 480 published genome-wide asso-
ciation studies.
16,17At the same time, however, interest was
rising in the second approach: to significantly improve
DNA sequencing technology to a point where an indi-
vidual’s entire genome could be sequenced at very low
cost. A combination of two kinds of arguments were
advanced supporting this approach, focusing on functional
utility and economics, respectively. 
The gist of the functional arguments was that sequenc-
ing of individuals is intrinsically more informative and
flexible than array-based interrogation of known sites of
variation and that, variation aside, any improvements in
sequencing cost and capability could be quickly applied
to numerous general aspects of biology that are critical
to understanding gene function, traits, and health and
disease.
18,19 The relative advantages of sequencing have
long been recognized. Unlike array analyses, sequenc-
ing: (i) does not require variations to be preidentified;
(ii) can more readily accommodate more complex vari-
ations than single nucleotide changes and very short
inserts or deletions; and (iii) need not focus on variations
that are common in large populations vs rare or unique
variations. In consequence, as sequencing technology has
improved, it has increasingly been integrated into asso-
ciation studies of variation.
20-23
However, these advantages of sequencing were coun-
terbalanced by their high cost, a situation well illustrated
by the $3 billion US cost of the HGP itself. It is here that
economic arguments were advanced suggesting that dra-
matic improvements in sequencing were feasible that
might ultimately enable an individual’s genome to be
sequenced for 1000 to 10 000 USD.
18 On an empirical
level, sequencing technology has appeared to exhibit a
historical trend of exponentially decreasing costs with
time as measured by sequenced base pairs per dollar at
a given error rate, a situation frequently compared with
“Moore’s Law” in computing,
24 which noted that com-
puting power measured by the integrated circuit tran-
sistor density doubled roughly every 2 years at constant
cost (Figure 2).
18,25To get genome sequencing costs down
to $1000 would require cost and throughput improve-
ments of an additional 4 to 5 orders of magnitude, so the
question of economic feasibility ultimately turned on
whether new methods could enable this very large
improvement. 
Here, the HGP again gave grounds for optimism, for
even though the HGP itself only achieved 100-fold
improvements, it achieved this largely by refining, minia-
turizing, and robotically scaling up, but not fundamen-
tally changing, a Sanger sequencing method initially
developed over 20 years earlier (Table II). If such meth-
ods were capable of 100-fold improvement, considerably
greater improvements might be expected from more rad-
ically changing sequencing chemistry, signal generation
and detection, and instrumentation in ways that could
integrate some of the vast advances in chemistry and
Basic research
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Date Event Size of sequence (bp) Reference
1957 First sequence mutation identified responsible for disease 1 amino acid  (Ingram 1957
2) 
(sickle cell vs normal hemoglobin)
1965 First sequence of a single complete gene 77 bases (Holley, Apgar et al 1965
3)
1976-1977 Sequencing of first viral genomes 3562 bases (MS2 RNA phage) (Fiers, Contreras et al 1976
4;
5375 bases (φ X174 DNA phage) Sanger, Air et al 1977
5)
1975-1977 Maxam/Gilbert and Sanger DNA sequencing methods (Sanger and Coulson 1975
6; 
Maxam and Gilbert 1977
7;
Sanger, Nicklen et al 1977
8)
1994 First commercial bacterial genome sequence 1.7Mbp (Helicobacter pylori) (Nature Genetics, May 1996
9)
1995 First published bacterial genome sequence 1.83Mbp (Haemophilus influenzae) (Fleischmann, Adams et al 1995
10)
1998-2000 Genome sequences of first animals 100Mbp (Caenorhabditis elegans) (C. elegans Sequencing
120Mbp (Drosophila melanogaster) Consortium 1998,
11 Adams, 
Celniker et al 2000
12)
2001 Two draft sequences of human genome  ~3Gbp (Lander, Linton et al 2001,
13
Venter, Adams et al 2001
14)
2003 Completion of public Human Genome Project (Collins, Morgan et al 2003
15)
Table II. Development of DNA sequencing. 
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microfabrication, and process control that had accrued
over the preceding 20 years and been put to good use in
many other fields. The HGP also directly provided an
important resource for realizing this strategy: the refer-
ence human genome sequence itself, as this could serve
as a template against which reads obtained by new tech-
nologies could be located, allowing new human genomes
to be assembled at least initially by “resequencing” vs de
novo assembly. This reduces the burden on new sequenc-
ing methods by allowing them to generate useful data
with shorter reads and higher base call error rates than
would generally be needed for de novo assembly,
although de novo assembly of genomes using new
sequencing technology remains an important goal.
Next-generation sequencing
Researchers were quick to work out sequencing
approaches along the lines indicated in these arguments,
and commercial products emerged soon, giving rise to
next-generation sequencing (NGS). Soon granting agen-
cies promised funding for support, and a ~10M USD
competition was announced for rapid, accurate genomic
sequencing, generating increased coalescence around
target goals for dramatic improvements to sequencing
technology.
26,27,28 Detailed reviews and comparisons of
NGS approaches have been published.
18,29,30
Among the earliest NGS methods were polony sequenc-
ing (the Polonator) and 454 Life Sciences.
31,32,33 Both meth-
ods amplify DNA templates onto microbeads that are
packed onto two-dimensional arrays for sequencing,
thereby achieving enormous economies of scale com-
pared with Sanger sequencing, and each achieved ~25-
fold better cost per bp compared with HGP (Figure 2).
However, each uses different sequencing chemistry and
arraying technology, giving rise to many technical trade-
offs. Together they proved the general point that great
improvements in sequencing efficiency were indeed
within reach, but also that the precise character and
degree of improvement would depend closely on the
novel technologies employed and the ingenuity with
which they could be integrated. A second wave of devel-
opment introduced methods by Illumina and ABI that, by
very different means, have improved the utility and costs,
(Figure 2)
34,35 and hence use of these systems is becoming
widespread for both large scale and “deep” sequencing
applications, and both are under continuous development.
Two complete cancer genomes were recently sequenced,
one with each platform.
36,37 Further rounds of innovation
have yielded a diverse set of newer NGS methods. For
instance, a number of “single-molecule” sequencing meth-
ods are now available or in development. These methods
avoid the need to make thousands to millions of copies of
DNA template molecules on microbeads or surfaces to
assure that sequencing operations generate sufficient sig-
nal to read individual bases accurately, and instead use
highly sensitive optics to detect bases at the single mole-
cule level; this allows even denser packing of DNA tem-
plates and further efficiencies in sequencing chemistry.
While Helicos Biosciences has commercialized a single-
molecule system that simply arrays single template mol-
ecules on a surface and uses sequencing cycle similar to
the methods above, Pacific Biosciences is developing a
system in which enzymes and templates are tethered to
the bottom of nanofabricated wells and which monitors
the signals generated by sequencing chemistry in real-
time vs artificial cycles.
38,39 Here, the nanofabricated wells
enable substantially increased accuracy of single molecule
base incorporation events. Finally, on another track, the
company Complete Genomics, Inc has developed a
method whereby very compact self-assembling amplicons
of template DNAs called “nanoballs” are flowed onto a
nanofabricated grid of ~300nm spots at 700 to 1300 nm
center-to-center distances. Three complete human
genomes were sequenced with this method (as of January
2010) with an average consumable cost of $4400 and as
low as $1500 for 40X coverage.
40
Personal genomes in progress - Lunshof et al Dialogues in Clinical Neuroscience - Vol 12 . No. 1 . 2010
51
Figure 2. Exponential trend of sequencing costs in base pairs per USD
(bp/$), a trend often compared with Moore's Law (see text). See
ref 25 for details.
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These developments suggest that technology capable of
meeting the cost target of $1000 or less for a diploid
human genome sequence is within reach. Indeed, the in-
depth resequencing of individual human genomes has now
been demonstrated several times by NGS developers to
demonstrate that their methods have come of age. There
are now published full genome sequences for at least
seven individuals,
40 with some having been sequenced by
more than one method. There are also tens—and perhaps
hundreds—of additional unpublished or partly published
genomes (see, eg, refs 36,37),while the lower-coverage 1000
Genomes Project
20,21 continues. Clearly, the age of personal
genomics is now close at hand. 
The PGP
As described in the first section, one of the PGP’s central
aims is to develop a publicly available, fully consented
database containing comprehensive human genome and
phenome data for its research participants. Such inte-
grated datasets are fundamental drivers of progress in
functional genomics and enable systems biology-based
insights into the mechanisms of human health and dis-
ease.
41 PGP studies will look beyond inherited genomes
to include somatic and epigenetic variation data, as well
as relevant microbiome, transcriptome, immunity-reflect-
ing “VDJ-ome” and phenome data to develop compre-
hensive profiles. By developing high-resolution data pro-
files for each participant, and multiplying that by a large
(up to 100 000) participant population, the PGP will also
generate valuable data describing the kinds and distrib-
utions of variation that exist in populations. Although an
improved understanding of human health and disease is
a central aim of the PGP, its focus is considerably broader
and will enable research into the social and behavioral
sciences using personal genomic data. Finally, the PGP’s
flexible study protocol and public and distributed
approach to research enables it to keep pace with
sequencing and other technological advances while
simultaneously driving these developments.
Integrated personal genomes: inherited, somatic, envi-
ronmental genomics 
If the PGP is to fulfill its mission to address the multidi-
mensional complexity of human biology, it must encom-
pass multiple interacting “-omes.” For example, a per-
son’s diet will have a profound influence upon her or his
somatic gene expression as well as the genomic and pro-
teomic activity of the person’s microbiome. It will also
affect the metabolome. Similarly, an individual’s envi-
ronmental exposures to pollutants will have a direct
bearing on her or his immunological response and there-
fore, on the VDJ-ome. Germline alleles will affect how
one metabolizes drugs, which will have myriad effects on
an individual’s physiological and behavioral phenotypes.
Genomes (vs exomes)
In its early phase, given the then-current cost of genomic
sequencing, the PGP planned to focus on exomes rather
than whole genomes as a way to affordably expand the
project to large numbers of participants. Despite repre-
senting only 1% to 2% of the 6 billion base pairs in a
human genome, the exome contains all protein-coding
exons and therefore provides access to the majority of
known functional variants.
48,49,50 However, continued
improvements in genomic sequencing have produced
price declines that have rendered whole-genome
sequencing significantly cheaper per base pair than
exome sequencing. The PGP, as a result, has determined
that whole-genome sequencing is cost-justified given the
relatively high price of exomes and the additional infor-
mation supplied by whole-genome sequences of PGP
participants.
51 See also Table III for the various “omes.”
Phenomes
Detailed phenotype data is required to categorize and,
ultimately, understand the phenotypes that the PGP
seeks to explore. However, the vastness of the human
phenome, defined as the physical totality of human traits
at all levels, from the molecular to the behavioral, will
require new strategies that permit high-throughput trait
collection while yielding accurate and standardized phe-
notypic data. With regard to the cellular and molecular
phenotypes, the PGP collects participant tissue samples
and develops cell lines that are then deposited and pub-
licly accessible through established biobanks.
52,53
As the PGP expands it is exploring Web-based, high-
throughput behavioral phenotype data-collection mod-
els pioneered by leading public and private researchers.
While the reliability and validity of self-reported traits
is a concern, particularly for phenome research con-
Basic research
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54,55 Web-based assessments provide dis-
tinct opportunities for “dynamic phenotyping” based on
a particular individual’s prior genotype-phenotype asso-
ciations.
56The multimodal capabilities of Web-based trait
collection instruments, combined with their low cost of
implementation at large scales, seem likely to accelerate
the ability of studies like the PGP to effectively explore
new corners of the human phenome.
The PGP is also taking advantage of recent advance-
ments in health information technologies to assist par-
ticipants and researchers alike in structuring and access-
ing the massive amounts of personalized data generated
by the project. The emergence of online Personally
Controlled Health Record (PCHR) platforms and other
novel tools enables individuals to collect and manage
their own health data—including health history, med-
ication, allergy, immunization, biometric and other data
types
57,58,59—and can be developed for integrated data
entry, access and dissemination by both the individual
and third-party researchers or data providers, including
health care providers.
Enviromes
The picture of genome and phenome is incomplete with-
out the envirome. The envirome can be described as the
totality of equivalent environmental influences con-
tributing to all disorders and organisms.
60 The mode of
response of an organism to the environment that is
reflected in its phenotype is constrained by its unique set
of genetic variations and the environmental influences on
gene expression. Therefore, a comprehensive approach is
required to describe the envirome systematically in con-
junction with genome and phenome information. The rel-
evant envirome data is too large and complex to be
reported, managed, or analyzed manually. The creation of
phenome-genome and genome-envirome networks has
been suggested in order to relate phenome and envirome
information to potential disease-associated genes.
61
Microbiomes
Even though microbial cells are estimated to outnumber
human cells in a single individual by a factor of ten, we
know very little about the microbes that live in and on us,
including what mixture of bacteria, viruses, and other
micro-organisms constitute a “normal” human micro-
biome and how those organisms impact different biolog-
ical states.
62 Major efforts such as the Human Microbiome
Project are under way to characterize the microbiota at
different body sites in humans and to assess how variation
in microbial communities is associated with states of
health and disease.
63 The PGP takes advantage of the
unique availability of comprehensive participant profiles
and uses them to explore interactions between host
genetic and phenotypic variability alongside the genomic
variation in the microbes that colonize them.
64
The VDJ-ome
The Church Lab at Harvard Medical School is develop-
ing techniques for characterizing the repertoires of B-
and T-cell receptors in individual humans from blood
samples and correlated across time with personal expo-
sure histories, with an ultimate goal of characterizing
individuals repertoires of linkedVDJ and VJ sequences.
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Personal genome: Entire diploid human genome of a single individual representing 6 billion base pairs.
Exome: All exons, representing 1% to 2% of the entire human genome.
Phenome: Set of all traits in an organism, at all levels, or one of its subsystems, including morphology, physiology, and behavior.
42,43
Envirome: The totality of equivalent environmental influences contributing to all disorders and organisms.
44
Microbiome (human): The ecological community of commensal, symbiotic, and pathogenic microorganisms that share our body space.
45
VDJ-ome: The repertoire of rearranged V, D, and J genome segments present in an individuals's B and T immune cells at any given time (see 
Table IV).
Transcriptome: The set of all RNA molecules, including mRNA, rRNA, tRNA, and noncoding RNA produced in one or a population of cells.
46
Epigenome: The totality of programmed biochemical and structural modifications to genomic DNA that regulate organism or phenotype 
development.
Metabolome: Total set of metabolites generated by an organism, or subsystem.
Proteome: The entire set of proteins expressed by a genome, cell, tissue or organism at a given time under defined conditions. There are 
more proteins than genes.
47
Table III. The “omes.”
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ticipants and their self-reported data, and will yield a
database of unprecedented depth describing the diver-
sity and time development of human immune responses
of large numbers of individuals in their life contexts.
Tissue reprogramming
The PGP also applies advances in tissue reprogramming
techniques to tissue samples collected from PGP partic-
ipants. Cells from collected somatic tissues are repro-
grammed into induced pluripotent stem (iPS) cells
68 and
made to differentiate into the cell types that are targeted
for functional analysis. These methods enable experi-
mental access to diverse tissue types that would other-
wise be unobtainable from human subjects but are rou-
tinely analyzed in model organisms, and thus, PGP
participants can effectively serve as human model organ-
isms. By examining multiple cell types from a single indi-
vidual, differences in physiological states within and
between tissues can be compared within a single PGP
participant and/or across the entire PGP cohort. This
approach also permits researchers to elucidate connec-
tions between genetic variation and variation in other
molecular traits, such as gene expression or epigenetic
modifications.
69 Stored fibroblast cell lines provide
researchers with access to renewable supplies of differ-
ent tissue types from PGP participants. 
The PGP: from personal to public genomes
The potential benefits arising from large-scale and inte-
grated human genomic datasets are immense.
70The util-
ity of such research, however, depends upon the respon-
sible development and widespread availability of such
comprehensive datasets, which in turn depends on
describing and addressing the various ethical, legal and
social challenges. Those challenges include a standard set
that are inherent to any research involving human sub-
jects, as well as certain challenges that are unique to
“public genomics”
71 research involving publicly available,
identifiable whole-genome sequence data, such as the
model pioneered by the PGP. We use the term “public
genomics” to denote research studies that possess the
following three critical attributes.
Integrated data
The various data types, including genomic and phenomic
or trait data, are accessible in a linked format, such as a
PCHR or other integrated data structure. Through this
explicit linkage of data it is possible to ascertain the
complete list of available traits and genetic variants for
any given participant. Integration also facilitates partic-
ipant-researcher interactions, longitudinal study and
recontact and, crucially, simultaneous investigation of the
full range of complex trait associations. Although par-
ticipants need not be explicitly identified, integrated data
sets that include both genomic and phenomic data will
be identifiable in most cases. For this reason, participants
must be made explicitly aware of the probability that
they will be identified with their publicly available data,
rendering promises of perfect privacy, anonymity, or con-
fidentiality impermissible within the public genomics
model. However, the promise of privacy need not give
way to a promise of publicity.
Open access
Data sets and tissues are made publicly available with
minimal or no access restrictions (including researcher
qualifications and cost), and are generally transferable
outside the original research study to be utilized by and
combined with data from third parties. Well-developed
data structures and intellectual property licenses are
important components of this characteristic. Developing
datasets that are not only publicly available but also eas-
ily portable fosters the development of a genomic com-
mons, allows data validation by third parties, and enables
the use and application of data in novel contexts that
may not be foreseeable at the time of collection, thereby
Basic research
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The adaptive immune system 
The adaptive immune system enables individuals to respond to 
their unique exposure histories to pathogens and environmental 
antigens, and possibly to cancerous mutations in their own cells, by
generating and modulating expression of >10
12 unique antibodies
from B cells and T cell receptors.
65 Antibody diversity derives from
programmed stochastic rearrangements in maturing B cells of ~40
V, 23 D, and ~5 J functional genomic segments into VDJ heavy
chains, and ~35 V and ~5 J segments into VJ light chains (κ or λ) in
B cells, that are further randomized by somatic hypermutation; a
similar process occurs in T cells.
66 NGS methods are now allowing
researchers to identify and analyze expressed VDJ sequences in
depth.
67
Table IV. The adaptive immune system and the VDJ-ome.
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ity and broadening the genomic research community.
Voluntary and informed participation
Satisfaction of the first two criteria publication of an inte-
grated dataset in an open-access format necessitates that
a premium be placed on receiving truly voluntary and
informed consent from participants in public genomics
research projects. Given the yet-unknown outcomes and
the potential personal, familial, and social risks associated
with such research, enrollment is only acceptable under
an informed consent protocol that is specially designed
to meet the highest standards of human research subjects
protection in view of these conditions.
The study protocol
The PGP aims to produce public genomics research—
and to develop and evaluate associated technologies
and research—on a large and expanding scale. In
October of 2008, the PGP published the first inte-
grated set of DNA sequences, traits, and tissues col-
lected from ten participants (the “PGP-10”) enrolled
in a pilot study initiated in 2005. Today, the PGP is
incrementally expanding its cohort toward 100 000
participants. More than 12 000 individuals had regis-
tered to participate in the PGP as of February 2010. In
the following section we highlight significant features
of the PGP study protocol as it is implemented for the
enrollment of the first 100 participants (“PGP-100”)
and summarized in Table V. 
Public genomes: adding to ELSI
The practice of public genomics poses its own challenges,
especially for the organization and governance of human
subjects’ research, forcing us to critically reassess current
frameworks and practices. In order to pursue innovative
research in a responsible manner, the PGP has devel-
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Table V. Overview of PGP study protocol. 
Adapted from ref 52: Angrist M. Eyes wide open: the personal genome project, citizen science and veracity in informed consent. Pers Med. 2009;6:691-699.
Copyright © Future Medicine 2009
￿ Review and sign “mini-consent” form.
￿ Eligibility questionnaire about family circumstances and privacy preferences.
￿ Entrance exam to ensure informed consent; includes potential risks of participating, project protocols, and basic
   genetics.
￿ Review of full PGP consent form.
￿ Submit information or delete account.
￿ Consent to participate.
￿ Collection of baseline trait data via questionnaire and a personal health record. Includes allergies, 
   immunizations, medical history, medications, physical traits and measurements, diet, ethnicity/ancestry, lifestyle, 
   and environmental exposures.
￿ Participants asked to make a financial pledge (does not impact enrollment decisions).
￿ Identity verification and provision of mailing address.
￿ Submission of application for enrollment. Individuals selected to continue the enrollment process will receive an 
   enrolment kit by mail, including saliva collection materials.
￿ Participants may be interviewed by one or more PGP staff to verify identity and consent, confirm familiarity with 
   study protocols, and/or review trait questionnaire responses. Blood samples, saliva sample, and/or skin cells may 
   be collected.
￿ Tissue samples prepared for DNA sequencing and other biological analyses.
￿ Participants opt-in to have their profiles made available on a publicly accessible Web site, or withdraw from the 
   study.
￿ Establishment, distribution and analysis of cell lines for research.
￿ Information collected for 25 years. Participants can leave the study at any time.
￿ Data Safety Monitoring Board monitors the impacts of the PGP on enrolled participants. Quarterly emails 
   inquire about adverse events.
￿ Additional trait data and tissue samples may be requested periodically.
Eligibility
screening
Pre-
enrollment
Enrollment
Ongoing
participation
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relevant to ELSI. 
Open consent 
The “open consent” model developed by the PGP is
designed to address the set of challenges associated with
the creation of datasets where it may be possible to iden-
tify individual participants with their genomic and other
data. The open consent model assumes that, in such a
context, conventional assurances of anonymity, privacy
and confidentially are impossible and should not serve
as any part of the foundation for the informed consent
protocol.
72,73 Due to the structure of public genomics pro-
jects such as the PGP, and their associated datasets, while
privacy and confidentiality can be protected they cannot
and should not be guaranteed to participants. This prac-
tice ensures veracity, which we regard as a necessary—
though not sufficient—prerequisite for the exertion of
substantive autonomy. It is only through veracity that the
criteria underlying truly informed consent can be satis-
fied.
Open consent is therefore based on complete openness
and transparency with regard to all aspects of participa-
tion, including the potential for reidentification and the
reality that there may be other risks that are unidenti-
fiable at the time of consent. Predicting all potential risks
is by definition impossible and even a list of known pos-
sible risks is unlikely ever to be comprehensive.
Data sharing—and the risks of public genomes
The PGP’s informed consent process begins with an
extensive pre-enrollment educational examination
designed to ensure a potential participant’s ability to
understand the specific nature of the data collected and
the risks presented by public genomics research. For indi-
viduals who demonstrate the needed proficiency, the spe-
cific informed consent agreement that follows includes a
lengthy but “noncomprehensive list of hypothetical sce-
narios that could pose risks” for participants and their
families (Table VI). Participants are warned that “the com-
plete set and magnitude of the risks that the public avail-
ability of [your genomic data] poses to you and your rel-
atives is not known at this time.” It is crucial that
participants understand that once identifying genetic and
trait data and tissues are released into the public domain
for the express intent of broad dissemination and use by
third parties it will be, in all likelihood, impossible to effect
a meaningful retraction at a later date.
The PGP’s informed consent agreements and broader
study protocol are developed in continuous close interac-
tion with the Harvard Medical School Committee on
Human Studies. The project is also overseen by an inde-
pendent Data Safety Monitoring Board. Removing poten-
tially disingenuous promises of anonymity, privacy, and
confidentiality, while seeking to comprehensively and
openly describe both known and unknown risks of partic-
ipation, helps to ensure that research participants are as
Basic research
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Potential risks of participation in the PGP as described in the consent form (Abbreviated) 
￿ The risks of public disclosure of your genetic and trait information could affect your employment, insurance and financial well-being and 
social interactions for you and your family. 
￿ Anyone with sufficient knowledge and resources could take your DNA sequence data and/or posted trait information and use that data, 
with or without modification, to: (i) infer paternity or other features of your genealogy; (ii) claim statistical evidence that could affect your 
employment, insurance or ability to obtain financial services; (iii) claim relatedness to criminals or incriminate relatives; (iv) make synthetic 
DNA and plant it at a crime scene, or otherwise use it to falsely identify you; or (v) reveal the possibility of a disease or unknown propensity 
for a disease.
￿ Whether or not it is lawful to do so, you could be subject to actual or attempted employment, insurance, financial, or other forms of 
discrimination or negative treatment on the basis of the public disclosure of your genetic and trait information by the PGP or by a third party.
￿ The distribution of your cell lines could result in the creation and further distribution by a third party of additional cell lines, organs, or 
tissues containing your DNA for research, commercial, clinical, or other uses, including certain forms of assisted reproduction, some of which 
you may find objectionable or upsetting.
￿ If you have previously made available or intend to make available genetic information in a confidential setting, for example in another 
research study or in a clinical trial, the data that you provide as part of the PGP may be used, on its own or in combination with your 
previously shared data, to identify you as a participant in otherwise confidential genetic research or trials.
Table VI. Potential risks of participation.
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informed as possible about the nature of public genomics
research and, simultaneously, safeguards the trustworthi-
ness of scientists and of scientific research in general.
Return of research data to participants
Research volunteers have been traditionally treated as
“objects” of study who have no intrinsic rights to the
data generated by their participation.
74 Today, we see
that study participants are increasingly asking for access
to their data
75 and that available information and com-
munication technologies have turned the return of
research results into a feasible option. While some
researchers adhere to the traditional viewpoint that
research subjects should not or cannot receive identifi-
able research data, some have suggested legal and ethi-
cal grounds for finding that researchers possess the
obligation to inform their participants of certain results,
particularly when they are clinically actionable.
76
However, defining the scenarios in which research
results should be reported—and how to report such
results—remains a challenging issue. The medical, finan-
cial, and psychosocial risks of disclosing variants of
known and unknown clinical significance require that a
careful distinction be made between those variants in
which convincing clinical observational data exists and
those in which disease association is less robust; a dis-
tinction that can influence both when and how to return
results. Other concerns that have been voiced include
the uncertainty surrounding regulations governing the
return of genomics research results directly to partici-
pants, the impact of false-positive and/or false-negative
results, as well as the “incidentalome,”
77 and in the con-
text of commercial direct-to-consumer testing, the con-
cern that obtaining results could lead to a “raiding of the
medical commons.”
78
As new models of genomic research and commerce
emerge, new mechanisms for communicating results to
participants are also being explored. Many of these new
models embrace a high level of involvement from their
participants and, in return, may rely on some combina-
tion of education, informed consent, and intermediation
to return data in a responsible fashion.
79
The public genomics model adopted by the PGP utilizes
the first two approaches while foregoing the third, opting
to return data directly to research participants without
the required intervention of an intermediary. The advan-
tages of direct data return and participant communica-
tion are blunted by the partial shifting of the interpreta-
tive burden from the clinician to the researcher. The PGP
has approached this issue by focusing on data disclosure
via the Preliminary Research Report (PRR), which con-
tains a noncomprehensive list of genetic variants present
in the participant’s DNA sequence data currently
thought to have a likelihood of clinical relevance among
individuals possessing such variants.
This preliminary identification of potentially significant
variants is not intended to substitute in any way for pro-
fessional medical advice, diagnosis or treatment. It lever-
ages current knowledge by combining an evolving set of
filtering algorithms and the use of existing variant data-
bases— neither of which can be expected to have 100%
accuracy in identifying truly pathogenic variants given
the gaps in current scientific understanding. Participants
are specifically instructed to confirm any potentially sig-
nificant findings in consultation with their health care
provider. It is possible that the increased rate of data
return from public genomics research—as well as from
commercial providers of personal genomic data—will
help speed the creation of universal standards for clini-
cal genomic interpretation that will help shift some of
the interpretative burden back away from public
genomics researchers.
Outlook: the PGP from 10 to 100 000
After publishing initial data from its first 10 participants
in 2008, the PGP has continued to broaden the scope of
the information it is collecting and publishing while
simultaneously commencing the next stages of partici-
pant enrollment. From exome to whole-genome
sequence data, the development and release of the GET-
EvidenceBase tool
80 for generation of Preliminary
Research Reports, and the publication of substantial
scholarship based on the PGP data generated to date,
the project’s progress has been substantial. The PGP is
now supported by PersonalGenomes.org, a 501(c)(3)
non-profit charity that coordinates the international
efforts of the PGP with other collaborative public
genomics research projects around the world. Both the
PGP and PersonalGenomes.org continue to strive to
develop and disseminate genomic technologies, pheno-
typing strategies, and knowledge on a global scale and
to produce tangible and widely available improvements
in the understanding and management of human health
in a responsible fashion.  ❏
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Avances en el genoma personal: 
desde el Proyecto Genoma Humano al
Proyecto Genoma Personal
El costo de una secuencia del genoma humano diploide se ha
reducido desde cerca de 70 millones de dólares a 2000 dólares
desde 2007, aunque los estándares de la redundancia han
aumentado de 7 a 40 veces para mejorar los índices de
demanda de genotipo. Junto con el bajo retorno de inversión
para los polimorfismos de nucleótidos únicos comunes, esta
situación ha causado un aumento significativo del interés en
correlacionar las secuencias genómicas con una completa
información ambiental y de rasgos (GAR). El costo de las fichas
médicas electrónicas, de las imágenes y de la información
microbiológica, inmunológica y conductual también está
reduciéndose rápidamente. El compartir tal conjunto de infor-
mación y sus interpretaciones con una diversidad de investi-
gadores y sujetos de investigación pone de relieve la necesi-
dad de contar con modelos de consentimiento informado
capaces de estar orientados hacia nuevos temas de privacidad
y otros, además de flexibilizar los recursos de datos compar-
tidos que permitan disponer de materiales e información con
mínimas restricciones de uso. Este artículo examina el esfuerzo
del Proyecto de Genoma Personal para desarrollar una base
de datos de GAR como un recurso de genómica pública
ampliamente accesible tanto a investigadores como a parti-
cipantes de las investigaciones, respetando los estándares más
elevados de la ética de la investigación. 
Les progrès du génome personnel : 
de l’étude du génome humain à l’étude du
génome personnel
Le coût de séquençage d'un génome diploïde humain a
chuté de 70 millions de dollars à 2 000 dollars depuis 2007,
bien que les standards de redondance aient augmenté de 7
à 40 fois afin d'améliorer le taux d'identification des bases.
Associé au faible retour sur investissement des polymor-
phismes de simples nucléotides (SNP), cette situation explique
l’intérêt accru pour la corrélation des séquences des génomes
avec des données complètes environnementales et de traits
(GET). Les coûts des enregistrements numériques médicaux,
de l’imagerie et des données microbiennes, immunologiques
et comportementales chutent aussi rapidement. Le partage
de telles bases de données GET intégrées et de leurs inter-
prétations avec un grand nombre de chercheurs et de sujets
de recherche souligne la nécessité de modèles de consente-
ment éclairé nécessaires à cette nouvelle protection des don-
nées personnelles et autres problématiques, en plus des
besoins de flexibilité des ressources requises pour le partage
des données, permettant en plus une utilisation peu restric-
tive de ces matériels et données. Cet article analyse les efforts
du Projet du Génome Personnel afin de développer une base
de données GET en tant que ressource génomique publique,
largement accessible à la fois aux chercheurs et aux partici-
pants à la recherche, tout en respectant les standards les plus
élevés de l’éthique de la recherche.
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